[HTML] nih.gov

[HTML][HTML] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti, A Gelibter… - World Journal of …, 2013 - ncbi.nlm.nih.gov
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …
被引用次数：16 相关文章

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti, A Gelibter… - WORLD JOURNAL OF …, 2013 - iris.uniroma1.it
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti… - World journal of …, 2013 - pubmed.ncbi.nlm.nih.gov
Aim To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. Methods We designed a …
[PDF] academia.edu

[PDF][PDF] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti, A Gelibter… - World J …, 2013 - academia.edu
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …
[HTML] wjgnet.com

[HTML][HTML] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti, A Gelibter… - World Journal of …, 2013 - wjgnet.com
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …
[PDF] core.ac.uk

[PDF][PDF] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti, A Gelibter, L Moscetti… - World J …, 2013 - core.ac.uk
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

V Vaccaro, E Bria, I Sperduti, A Gelibter… - World Journal of …, 2013 - europepmc.org
Aim To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. Methods We designed a …

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

V Vaccaro, E Bria, I Sperduti, A Gelibter… - WORLD JOURNAL OF …, 2013 - iris.univr.it
To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-
rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. We designed a single-arm …

[引用][C] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

V Vaccaro, E Bria, I Sperduti, A Gelibter… - World Journal of …, 2013 - wjgnet.com
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer Home
English English 简体中文 Sign In BPG Management System F6Publishing-Submit a Manuscript …

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

V Vaccaro, E Bria, I Sperduti, A Gelibter… - World Journal of …, 2013 - europepmc.org
Aim To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. Methods We designed a …